Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study

MLA

Ding, Xiaomin, et al. “Efficacy and Safety of Fruquintinib as Third- or Further-Line Therapy for Patients with Advanced Bone and Soft Tissue Sarcoma: A Multicenter Retrospective Study.” Anti-Cancer Drugs, vol. 34, no. 7, Aug. 2023, pp. 877–82. EBSCOhost, https://doi.org/10.1097/CAD.0000000000001482.

APA

Ding, X., Liu, Y., Zhang, Y., Liang, J., Li, Q., Hu, H., & Zhou, Y. (2023). Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study. Anti-Cancer Drugs, 34(7), 877–882. https://doi.org/10.1097/CAD.0000000000001482

Chicago

Ding, Xiaomin, Yuan Liu, YaWen Zhang, Jinrong Liang, Qian Li, Haiyan Hu, and Yan Zhou. 2023. “Efficacy and Safety of Fruquintinib as Third- or Further-Line Therapy for Patients with Advanced Bone and Soft Tissue Sarcoma: A Multicenter Retrospective Study.” Anti-Cancer Drugs 34 (7): 877–82. doi:10.1097/CAD.0000000000001482.